Literature DB >> 10883894

EORTC Receptor and Biomarker Study Group Report: a sandwich enzyme-linked immunosorbent assay for vascular endothelial growth factor in blood and tumor tissue extracts.

P N Span1, N Grebenchtchikov, J Geurts-Moespot, J R Westphal, A M Lucassen, C G Sweep.   

Abstract

A four-antibody sandwich enzyme-linked immunosorbent assay (ELISA) for vascular endothelial growth factor (VEGF) for application in blood (serum and plasma) and tumor tissue extracts was set up within the framework of the EORTC Receptor and Biomarker Study Group (RBSG). Polyclonal antibodies against VEGF165 were raised in chickens and rabbits, and used in a previously described assay format. The assay was validated and characterized for use in serum, plasma and tumor tissue extracts. The resulting VEGF ELISA was found to be specific for VEGF165 and VEGF121, the main isoforms of VEGF. The assay showed good precision and parallelism in serial dilutions of samples. The assay was not susceptible to interference by heterophilic antibodies because avian antibodies (duck anti-chicken and chicken anti-VEGF) were used in the pre-analyte stage and mammalian antibodies (rabbit anti-VEGF and goat anti-rabbit) in the post-analyte stage. In conclusion, a sensitive, robust and specific VEGF ELISA has been developed. Research into the prognostic value of VEGF employing this assay is currently underway.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10883894     DOI: 10.1177/172460080001500210

Source DB:  PubMed          Journal:  Int J Biol Markers        ISSN: 0393-6155            Impact factor:   3.248


  11 in total

1.  A phase II study of cediranib as palliative treatment in patients with symptomatic malignant ascites or pleural effusion.

Authors:  S F Mulder; M J Boers-Sonderen; H F M van der Heijden; K C P Vissers; C J A Punt; C M L van Herpen
Journal:  Target Oncol       Date:  2014-01-21       Impact factor: 4.493

2.  Elevated levels of vascular endothelial growth factor in serum of patients with D+ HUS.

Authors:  D Maroeska Te Loo; Nienke Bosma; Victor Van Hinsbergh; Paul Span; Rob De Waal; Ruud Clarijs; C Sweep; Leo Monnens; Lambertus Van Den Heuvel
Journal:  Pediatr Nephrol       Date:  2004-05-13       Impact factor: 3.714

3.  Circulating VEGF levels in the serum of gastric cancer patients: correlation with pathological variables, patient survival, and tumor surgery.

Authors:  Anastasios J Karayiannakis; Konstantinos N Syrigos; Alexandros Polychronidis; Andrew Zbar; Gregory Kouraklis; Constantinos Simopoulos; Gabriel Karatzas
Journal:  Ann Surg       Date:  2002-07       Impact factor: 12.969

4.  Serum vascular endothelial growth factor: a prognostic factor in cervical cancer.

Authors:  Petra L M Zusterzeel; Paul N Span; Marja G K Dijksterhuis; Chris M G Thomas; Fred C G J Sweep; Leon F A G Massuger
Journal:  J Cancer Res Clin Oncol       Date:  2008-07-15       Impact factor: 4.553

5.  Semaphorin 3E expression correlates inversely with Plexin D1 during tumor progression.

Authors:  Ilse Roodink; Gürsah Kats; Léon van Kempen; Meritha Grunberg; Cathy Maass; Kiek Verrijp; Jos Raats; William Leenders
Journal:  Am J Pathol       Date:  2008-10-30       Impact factor: 4.307

6.  Immunoreactivity of anti-gelsolin antibodies: implications for biomarker validation.

Authors:  Nicole Haverland; Gwënaël Pottiez; Jayme Wiederin; Pawel Ciborowski
Journal:  J Transl Med       Date:  2010-12-20       Impact factor: 5.531

7.  Functional MRI techniques demonstrate early vascular changes in renal cell cancer patients treated with sunitinib: a pilot study.

Authors:  I M E Desar; E G W ter Voert; Th Hambrock; J J A van Asten; D J van Spronsen; P F A Mulders; A Heerschap; W T A van der Graaf; H W M van Laarhoven; C M L van Herpen
Journal:  Cancer Imaging       Date:  2012-01-12       Impact factor: 3.909

8.  αB-crystallin stimulates VEGF secretion and tumor cell migration and correlates with enhanced distant metastasis in head and neck squamous cell carcinoma.

Authors:  Chantal van de Schootbrugge; Johan Bussink; Paul N Span; Fred C G J Sweep; Reidar Grénman; Hanneke Stegeman; Ger J M Pruijn; Johannes H A M Kaanders; Wilbert C Boelens
Journal:  BMC Cancer       Date:  2013-03-18       Impact factor: 4.430

9.  The prognostic value of vascular endothelial growth factor in 574 node-negative breast cancer patients who did not receive adjuvant systemic therapy.

Authors:  P Manders; L V A M Beex; V C G Tjan-Heijnen; J Geurts-Moespot; T H Van Tienoven; J A Foekens; C G J Sweep
Journal:  Br J Cancer       Date:  2002-09-23       Impact factor: 7.640

10.  Impairment of cognitive functioning during Sunitinib or Sorafenib treatment in cancer patients: a cross sectional study.

Authors:  Sasja F Mulder; Dirk Bertens; Ingrid M E Desar; Kris C P Vissers; Peter F A Mulders; Cornelis J A Punt; Dick-Johan van Spronsen; Johan F Langenhuijsen; Roy P C Kessels; Carla M L van Herpen
Journal:  BMC Cancer       Date:  2014-03-24       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.